BRAIN Biotech Reports Solid Q3 Revenue Growth in BRAINBiocatalysts Segment

BRAIN Biotech AG has announced an 8.1% increase in revenue for its core segment, BRAINBiocatalysts, during Q3 of the 2024/25 fiscal year. This rise contributed to a total group revenue increase of 2.1%, reaching €13.5 million. The growth in the enzyme-focused segment is part of the company's strategy to focus on this area despite broader economic challenges. The BRAINBiocatalysts segment achieved €35.5 million in sales over the nine-month reporting period, marking a 3.4% increase compared to the previous year.

Despite an overall decline in group sales attributed to the BRAINBioIncubator segment, which faced a challenging economic climate, BRAIN Biotech maintained a solid cash position of €10.5 million. CEO Adriaan Moelker highlighted the company's focus on cost management and enzyme business as key contributors to this positive EBITDA change. The partnership with Corbion to develop the Perillic Active project highlights BRAIN's strategy to expand through collaborations.